OxFORD Asset Management LLP boosted its position in shares of Recro Pharma, Inc. (NASDAQ:REPH) by 364.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 203,430 shares of the specialty pharmaceutical company’s stock after acquiring an additional 159,619 shares during the quarter. OxFORD Asset Management LLP owned 1.07% of Recro Pharma worth $1,430,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the stock. Wells Fargo & Company MN increased its position in Recro Pharma by 3.0% during the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock valued at $150,000 after acquiring an additional 500 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Recro Pharma by 76.9% during the second quarter. Janney Montgomery Scott LLC now owns 22,085 shares of the specialty pharmaceutical company’s stock valued at $155,000 after acquiring an additional 9,600 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Recro Pharma during the first quarter valued at $156,000. KCG Holdings Inc. purchased a new stake in Recro Pharma during the first quarter valued at $173,000. Finally, Rothschild Investment Corp IL purchased a new stake in Recro Pharma during the second quarter valued at $141,000. Institutional investors own 65.06% of the company’s stock.
Shares of Recro Pharma, Inc. (NASDAQ REPH) opened at 8.72 on Wednesday. The stock’s market cap is $166.19 million. The company’s 50-day moving average price is $8.14 and its 200-day moving average price is $7.72. Recro Pharma, Inc. has a 52-week low of $5.81 and a 52-week high of $10.17.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.06. The business had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.90 million. Recro Pharma had a negative return on equity of 56.04% and a negative net margin of 46.75%. On average, equities research analysts forecast that Recro Pharma, Inc. will post ($2.35) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/10/11/oxford-asset-management-llp-boosts-position-in-recro-pharma-inc-reph.html.
A number of research firms recently commented on REPH. Zacks Investment Research cut Recro Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 31st. Janney Montgomery Scott cut Recro Pharma from a “buy” rating to a “fair value” rating and reduced their price objective for the company from $21.00 to $6.50 in a research report on Wednesday, June 14th. Roth Capital set a $20.00 price objective on Recro Pharma and gave the company a “buy” rating in a research report on Monday, July 31st. Finally, Piper Jaffray Companies set a $11.00 price objective on Recro Pharma and gave the company a “buy” rating in a research report on Tuesday, July 25th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $12.63.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.